Zymeworks earnings date
Want to see ZYME full AI Analyst Report?
Zymeworks (ZYME) Q1 2026 Earnings Report
ZYME Q1 2026 EPS Results
- Actual EPS
- -$0.59
- Consensus EPS
- -$0.30
- Beat/Miss
- Missed by -$0.29
- One Year Ago EPS
- -$0.30
ZYME Q1 2026 Revenue Results
- Actual Revenue
- $2.41M
- Expected Revenue
- $24.38M
- Beat/Miss
- Missed by -$21.97M
- YoY Revenue Growth
- -91.12%
Earnings Announcement Details
- Quarter
- Q1 2026
- Date
- 05/07/2026
- Time
- After Close
- Conference Call
- Thursday, May 7, 2026
Zymeworks's next earnings date is estimated for March 10, 2027, based on past reporting schedules.
Q1 2026 Earnings Call Audio
Q1 2026 Earnings Slide Deck
Q1 2026 Earnings Call Summary
The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.
The company reiterated near-term regulatory and operational milestones, including a U.S. PDUFA date of 08/25/2026 and an sBLA filing in China for first-line GEA, with near-term approval-triggered milestone payments of $250.0 million (U.S.) and $15.0 million (China) and management citing $440.0 million of anticipated regulatory milestones (U.S./EU/Japan/China) that, together with $403.8 million of cash, cash equivalents and marketable securities as of 03/31/2026 (up from $270.6 million on 12/31/2025), they expect to fund operations beyond 2028 assuming full execution of the $125.0 million repurchase plan; Q1 2026 revenue was $2.4 million versus $27.1 million a year ago, operating expenses were $49.5 million (Q1 2026) versus $52.7 million, and net loss was $44.2 million versus $22.6 million, while share repurchases have used ~$95.8 million of the $125.0 million program to buy ~3.93 million shares at an average $24.37 (total repurchases since 2024 ~ $155.8M for ~8.3M shares at ~$18.70, >10% of shares), leaving ~73 million common shares outstanding; clinical and R&D guidance included ZW191 dose‑optimization (≈60‑patient cohort fully enrolled) with median follow‑up ~7 months, ovarian ORR 56% (>=30% shrinkage in 68%, any shrinkage in 85%, DCR 94%) and at 6.4–9.6 mg/kg ORR 61% with disease control in all patients, endometrial ORR 40% (>=30% shrinkage in 50%, any shrinkage in 70%, DCR 80%) rising to ORR 57% at 6.4–9.6 mg/kg, responses seen from 3.2 mg/kg, ZW1528 IND now guided to 2027 (vs prior 2026), pan‑RAS ADC preclinical program delivered >117 novel inhibitors, three candidate ADCs (ZW439, ZW427, ZW418) were presented at AACR, DAR‑8 format was used, and the lead RAS ADC showed NHP tolerability with no body‑weight, skin or GI toxicity up to 120 mg/kg; additional data cadence was guided toward oncology meetings in 2026 (including ESMO GYN in June).
- Near-term Regulatory Catalysts for ZanatumabPDUFA date set for 08/25/2026 in first-line GEA (U.S.) and sBLA filing completed in China, creating visible near-term commercialization pathway with partners Jazz and BeiGene and potential for meaningful milestone and royalty revenue.
- Material Potential Milestone UpsidePotential near-term milestone payments include $250M upon U.S. approval from Jazz and $15M upon China approval from BeiGene; management cites anticipated regulatory milestone payments of $440M across U.S., Europe, Japan and China that underpin financial runway assumptions.
- Strong Cash Position and RunwayCash, cash equivalents and marketable securities of $403.8M as of 03/31/2026, up from $270.6M as of 12/31/2025 (+49.2%), with management expecting existing cash plus anticipated milestone payments to fund operations beyond 2028 (assumes milestones).
- Active Share Repurchase ProgramCompany has used ~$95.8M of its $125M repurchase authorization (~76.6% utilized) to acquire ~3.93M shares at an average price of $24.37; historically retired ~8.3M shares (~$155.8M deployed) representing >10% of common shares outstanding, reflecting disciplined capital allocation to increase per-share value.
- Compelling Phase 1 Data for ZW191 (FRα ADC)ZW191 showed notable activity in heavily pretreated ovarian and endometrial cohorts: ovarian cohort ≥30% tumor regression in 68%, any tumor shrinkage in 85%, disease control 94%, ORR 56% across dose levels; at 6.4–9.6 mg/kg confirmed ORR 61% and disease control in all patients at that range. Endometrial: ≥30% tumor regression in 50%, tumor shrinkage in 70%, disease control 80%, ORR 40% (all doses); at 6.4–9.6 mg/kg ORR 57% and disease control 86%. Median follow-up ~7 months with durability signals.
- Pan‑RAS ADC Platform and Preclinical ProgressPresented three new preclinical pan‑RAS ADC candidates (ZW439: Claudin 18.2; ZW427: L1CAM; ZW418: biparatopic PTK7) at AACR and proprietary TOPA payload advancement. Lead pan‑RAS ADC showed favorable xenograft efficacy, bystander activity, and promising NHP tolerability with no observed body weight loss, skin or GI toxicity up to 120 mg/kg in tolerability studies. ADCs are DAR‑8 formats enabling tumor-selective payload delivery.
- ZW251 Trial Expansion and TriTCE ProgressZW251 protocol broadened to include additional tumor types (e.g., squamous NSCLC and germ cell tumors) based on GPC3 expression rationale; ZW209 is IND‑ready and TriTCE portfolio remains a prioritized long‑term asset class.
- Operational and Leadership StrengtheningAppointed new CFO and General Counsel and completed full-time appointments for commercial and R&D heads to support capital allocation, dealmaking, and strategic execution.
ZYME Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 10, 2027 | 2026 (Q4) | 0.13- | -0.55 | ― | ― |
| Nov 09, 2026 | 2026 (Q3) | 2.272.28 | -0.26 | 976.92% (+2.54) | |
| Aug 06, 2026 | 2026 (Q2) | -0.57-0.62 | 0.03 | -2166.67% (-0.65) | |
| May 07, 2026 | 2026 (Q1) | -0.30-0.59 | -0.3 | -96.67% (-0.29) | |
| Mar 02, 2026 | 2025 (Q4) | -0.46-0.55 | -0.31 | -77.42% (-0.24) | |
| Nov 06, 2025 | 2025 (Q3) | -0.29-0.26 | -0.39 | 33.33% (+0.13) | |
| Aug 07, 2025 | 2025 (Q2) | -0.480.03 | -0.49 | 106.12% (+0.52) | |
| May 08, 2025 | 2025 (Q1) | -0.68-0.30 | -0.42 | 28.57% (+0.12) | |
| Mar 05, 2025 | 2024 (Q4) | -0.10-0.31 | -0.2 | -55.00% (-0.11) | |
| Oct 31, 2024 | 2024 (Q3) | -0.40-0.39 | -0.41 | 4.88% (+0.02) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


